ADDvise Group successfully places subsequent senior secured bonds of SEK 150 million at par

23-11-2022   Regulatory press release

ADDvise Group AB (publ) ("ADDvise" or the "Company") announces today that the Company has successfully placed a subsequent senior secured bond issue (the “Subsequent Bond Issue") in an amount of SEK 150 million under the Company’s existing senior secured bond framework with ISIN SE0015222088. Following completion of the Subsequent Bond Issue, the outstanding amount under the senior secured bonds will be SEK 650 million.

The transaction was significantly oversubscribed and placed at a price of 100.0% of par.

Completion of the Subsequent Bond Issue is subject to inter alia the approval of the requested amendments to the terms and conditions of the bonds pursuant to the written procedure that was initiated on 21 November 2022. Provided that such approval is granted, settlement is expected to occur no later than 16 December 2022.

Pareto Securities AB acted as sole bookrunner and Roschier Advokatbyrå as legal advisor in connection with the subsequent bond issue.

For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Hanna Myhrman, General Counsel
+46 709-82 92 23
hanna.myhrman@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 23 November 2022 at 16:55 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

Latest press releases

Interim report 2025, January 1–March 31

Regulatory

In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational…

Invitation to presentation of interim report January 1 – March 31, 2025

Non-regulatory

ADDvise Group publishes its interim report January 1 – March 31, 2025 on Friday, May 9, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report. Webcast If you wish…

Notice to the annual general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363–2115, hereby convenes the annual general meeting on 12 May 2025 at 10:00 CEST at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09.30 CEST. NOTIFICATION Shareholders wishing to attend the annual general meeting must: i)          be registered in the share register kept by Euroclear Sweden AB on the…

ADDvise raises approximately SEK 457 million in the rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…